Join our daily newsletter At The Bell to receive exclusive market insights
- Medibio (MEB) has entered a Clinical Trial Agreement (CTA) with MedBridge Healthcare for its Sleep Analysis of Depression Burden (SADB) trial
- The analysis aims to identify clinical depressive burden in patients who suffer from sleep disturbance
- MedBridge is a leading provider of sleep lab management services in the U.S and performs over 70,000 sleep disorder diagnostic procedures every year
- The parties are now fast-tracking patient recruitment
- Company shares ended the day 10 per cent in the green to close for 1.1 cents
Medibio (MEB) has entered a Clinical Trial Agreement (CTA) with MedBridge Healthcare for its Sleep Analysis of Depression Burden (SADB) trial.
This analysis aims to identify clinical depressive burden in patients who suffer from sleep disturbance.
MedBridge is an America-based, leading provider of sleep laboratory management services. It operates over 130 sleep disorder diagnostic centres and performs over 70,000 sleep disorder diagnostic procedures every year to provide long-term care for patients with sleep disorders.
“We are delighted to have MedBridge as a partner for our Sleep Analysis of Depressive Burden trial. Their expertise and reputation in sleep medicine in the United States is exemplary, and the size of MedBridge’s operations will help ensure that our SADB trial will be undertaken quickly and efficiently,” Medibio Managing Director Claude Solitario said.
MedBridge, in collaboration with Ohio Sleep Solutions in Columbus, will coordinate research guidelines and services for the SADB trial to help accelerate patient recruitment.
“The objective identification of depression in patients that suffer certain sleep disorders is an unmet need and we are pleased to be working with Medibio to fast-track patient recruitment for the SADB trial,” MedBridge Chief Development Officer John Mathias said.
Company shares ended the day 10 per cent in the green to close for 1.1 cents.
